DOI: 10.1161/circ.148.suppl_1.15054 ISSN: 0009-7322

Abstract 15054: Impact of Sarcoidosis-Related Admission in Patients With Heart Failure: A Nationwide Readmissions Database Analysis (2017-2020)

Qi Xuan Ang, Min Choon Tan, Jia Yi Tan, Jian Liang Tan
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Background: Sarcoidosis is an infiltrative systemic disorder that commonly involves the heart. Despite a higher prevalence of herat failure (HF) among patients with cardiac sarcoidosis (CS), data on these patients’ outcomes remain scarce.

Objective: This study aimed to assess the impact of concomitant CS in patients admitted for HF on in-hospital outcomes and 30-day readmission rates.

Methods: Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older who were admitted with a primary diagnosis of HF between 2017 and 2020. We stratified the cohort into two groups depending on the presence of sarcoidosis diagnosis. The in-hospital outcomes of both groups were assessed with weighted propensity score matching and multivariable analyses.

Results: Our analysis included 1,902,068 patients with a primary diagnosis of HF, whereby 9,343 (0.49%) patients had sarcoidosis. Via multivariable analysis, sarcoidosis was associated with an increased risk of prolonged hospital stays (aOR: 1.15 [95% CI: 1.08 - 1.23], p<0.01), 30-day readmission (aOR: 1.18 [95% CI: 1.11 - 1.25], p=0.01), and higher cumulative cost of hospitalization ($16,179 vs $13,421, p<0.01) among HF cohort. Sarcoidosis was not associated with an increased risk of early mortality. Among HF patients with sarcoidosis, the most common cause of 30-day readmission was cardiovascular causes (59%), where decompensated HF accounted for 50% of the readmission, followed by ischemic heart disease (2%), valvular heart disease (1%), and pulmonary embolism (1%).

Conclusion: In conclusion, our study suggests that HF patients with sarcoidosis had poorer in-hospital outcomes with prolonged hospital stays, higher 30-day readmission rates, and increased cumulative hospitalization costs. These findings merit increased effort in the early diagnosis and treatment of CS to improve outcomes in HF patients with sarcoidosis.

More from our Archive